Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients With Relapsed and Refractory Non-Hodgkin Lymphoma
Latest Information Update: 13 May 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- 07 May 2024 Planned primary completion date changed from 19 May 2024 to 19 May 2025.
- 07 May 2024 Status changed from recruiting to active, no longer recruiting.
- 19 May 2021 Planned End Date changed from 30 Nov 2020 to 19 May 2025.